AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
+0.06 (0.08%)
At close: Jun 14, 2024, 4:00 PM
+0.35 (0.44%)
After-hours: Jun 14, 2024, 7:59 PM EDT

AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of $246.77 billion. The enterprise value is $273.30 billion.

Market Cap 246.77B
Enterprise Value 273.30B

Important Dates

The next confirmed earnings date is Thursday, July 25, 2024, before market open.

Earnings Date Jul 25, 2024
Ex-Dividend Date Feb 22, 2024

Share Statistics

AstraZeneca has 3.10 billion shares outstanding.

Shares Outstanding 3.10B
Owned by Insiders (%) 0.01%
Owned by Institutions (%) 16.86%
Float 1.54B

Valuation Ratios

The trailing PE ratio is 39.40 and the forward PE ratio is 16.31. AstraZeneca's PEG ratio is 0.89.

PE Ratio 39.40
Forward PE 16.31
PS Ratio 5.18
Forward PS 4.53
PB Ratio 6.59
P/FCF Ratio 30.00
PEG Ratio 0.89
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.19, with an EV/FCF ratio of 33.22.

EV / Earnings 43.17
EV / Sales 5.74
EV / EBITDA 19.19
EV / EBIT 30.02
EV / FCF 33.22

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.92.

Current Ratio 0.89
Quick Ratio 0.69
Debt / Equity 0.92
Debt / EBITDA 2.43
Debt / FCF 4.20
Interest Coverage 5.44

Financial Efficiency

Return on equity (ROE) is 16.80% and return on invested capital (ROIC) is 10.37%.

Return on Equity (ROE) 16.80%
Return on Assets (ROA) 6.40%
Return on Capital (ROIC) 10.37%
Revenue Per Employee $529,600
Profits Per Employee $70,423
Employee Count 89,900
Asset Turnover 0.48
Inventory Turnover 1.67


In the past 12 months, AstraZeneca has paid $1.10 billion in taxes.

Income Tax 1.10B
Effective Tax Rate 14.80%

Stock Price Statistics

The stock price has increased by +9.37% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.

Beta (1Y) 0.17
52-Week Price Change +9.37%
50-Day Moving Average 75.24
200-Day Moving Average 68.26
Relative Strength Index (RSI) 59.75
Average Volume (30 Days) 5,088,068

Short Selling Information

Short Interest 6.67M
Short Previous Month 7.67M
Short % of Shares Out 0.27%
Short % of Float n/a
Short Ratio (days to cover) 1.37

Income Statement

In the last 12 months, AstraZeneca had revenue of $47.61 billion and earned $6.33 billion in profits. Earnings per share was $2.03.

Revenue 47.61B
Gross Profit 39.03B
Operating Income 8.76B
Pretax Income 7.43B
Net Income 6.33B
EBIT 9.11B
Earnings Per Share (EPS) $2.03
Full Income Statement

Balance Sheet

The company has $8.02 billion in cash and $34.55 billion in debt, giving a net cash position of -$26.53 billion or -$8.56 per share.

Cash & Cash Equivalents 8.02B
Total Debt 34.55B
Net Cash -26.53B
Net Cash Per Share -$8.56
Equity / Book Value 37.45B
Book Value Per Share 12.08
Working Capital -3.31B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $9.70 billion and capital expenditures -$1.47 billion, giving a free cash flow of $8.23 billion.

Operating Cash Flow 9.70B
Capital Expenditures -1.47B
Free Cash Flow 8.23B
FCF Per Share $2.66
Full Cash Flow Statement


Gross margin is 81.98%, with operating and profit margins of 18.40% and 13.30%.

Gross Margin 81.98%
Operating Margin 18.40%
Pretax Margin 15.61%
Profit Margin 13.30%
EBITDA Margin 29.92%
EBIT Margin 19.12%
FCF Margin 17.28%

Dividends & Yields

This stock pays an annual dividend of $1.45, which amounts to a dividend yield of 1.82%.

Dividend Per Share $1.45
Dividend Yield 1.82%
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio 71.60%
Buyback Yield n/a
Shareholder Yield 1.82%
Earnings Yield 2.57%
FCF Yield 3.33%
Dividend Details

Analyst Forecast

The average price target for AstraZeneca is $87.25, which is 9.62% higher than the current price. The consensus rating is "Buy".

Price Target $87.25
Price Target Difference 9.62%
Analyst Consensus Buy
Analyst Count 7
Revenue Growth Forecast (5Y) 7.38%
EPS Growth Forecast (5Y) 27.35%
Stock Forecasts

Stock Splits

The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.

Last Split Date Jul 27, 2015
Split Type Forward
Split Ratio 2:1


AstraZeneca has an Altman Z-Score of 3 and a Piotroski F-Score of 6.

Altman Z-Score 3
Piotroski F-Score 6